Postherpetic Neuralgia Clinical Trial
Official title:
Phase 1 Novel Topical Treatment for Post-herpetic Neuralgia
Shingles is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chicken pox. Some people experience continued pain even after the shingles rash and blisters have healed; this pain is known as postherpetic neuralgia. The purpose of this study is to evaluate the effectiveness of a new topical treatment for postherpetic neuralgia in adults.
After an initial infection of chicken pox, the varicella-zoster virus can remain dormant
inside nerve cells. Years later, the virus can be reactivated, causing a repeat outbreak
called shingles. The first symptom of shingles is usually a burning or tingling pain in one
particular location and on one side of the body. This pain can range from mild to severe.
Other possible symptoms of shingles include numbness and itching. After several days or 1
week, a rash of fluid-filled blisters similar to chicken pox appears. For most healthy
people, a case of shingles heals within a month. However, some people continue to feel pain
after the rash and blisters have resolved; this pain is known as postherpetic neuralgia.
Current treatments for postherpetic neuralgia include antiviral drugs, steroids,
antidepressants, anticonvulsants, and topical products. A new topical treatment consists of
a liquid product that is applied directly to the skin to let dry and form a thin,
transparent barrier film. In contrast to creams or ointments that can stay in contact with
skin for only minutes, this product remains intact on the skin for many hours, providing
sustained delivery of a drug or medication while maintaining barrier protection for the
skin. The purpose of this study is to evaluate the effectiveness of this new topical
treatment for postherpetic neuralgia in adults.
This study will last about 3 weeks and will include seven study visits on Days 1, 8, 9, 15,
16, 22, and 23. All study visits will include questionnaires on pain levels and an
examination and digital photos of the affected skin area. The study visit on Day 1 will also
include a urine pregnancy test and a review of medical and medication history. During the
study visits on Days 8, 15, and 22, one of three topical products will be applied to
participants' affected skin. The product will dry on the skin in 30 to 45 seconds.
Participants will then wait at the study site for 1.5 hours, after which they will record
the time when they experienced pain relief. At each of these three treatment visits,
participants will receive one of the following three topical products: Epikeia coatings with
aspirin, Epikeia coatings with local anesthetic, and Epikeia coatings alone. At these three
study visits, questionnaires, examinations, and digital photographs will occur both before
and after the products are applied to the skin. Throughout the study, participants will
record their pain levels and medications in a diary, which will be reviewed at all study
visits.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04546334 -
Erector Spinae Plane Block in Post-herpetic Neuralgia
|
N/A | |
Terminated |
NCT01744522 -
Leech Therapy for Postherpetic Neuralgia
|
N/A | |
Completed |
NCT01688947 -
Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)
|
Phase 2 | |
Completed |
NCT00478179 -
Study of a Bupivacaine Patch (Eladurâ„¢) to Treat Post- Herpetic Neuralgia
|
Phase 2 | |
Completed |
NCT04099706 -
Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT
|
N/A | |
Terminated |
NCT01603394 -
Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia
|
Phase 4 | |
Completed |
NCT01228838 -
Study of NGX-1998 for the Treatment of Postherpetic Neuralgia
|
Phase 2 | |
Completed |
NCT01251211 -
Botulinum Toxin in Peripheral Neuropathic Pain
|
Phase 4 | |
Completed |
NCT00612105 -
Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)
|
Phase 2 | |
Recruiting |
NCT04560361 -
The Analgesic Effect of Electroacupuncture on Postherpetic Neuralgia
|
N/A | |
Recruiting |
NCT05568186 -
Correlation Between Thermal Patterns of Infrared Thermal Imaging and Clinical Phenotype in Patients With Postherpetic Neuralgia
|
||
Recruiting |
NCT04664530 -
The Study on the Esketamine in the Treatment of Postherpetic Neuralgia
|
Phase 4 | |
Active, not recruiting |
NCT01508676 -
Effects of Pennsaid on Clinical Neuropathic Pain
|
N/A | |
Completed |
NCT00885586 -
Acupuncture in Herpes Zoster Neuralgia (ACUZoster)
|
Phase 4 | |
Completed |
NCT00981227 -
Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia
|
Phase 2 | |
Completed |
NCT00576108 -
A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)
|
Phase 2 | |
Completed |
NCT00238511 -
An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)
|
Phase 2 | |
Completed |
NCT00007501 -
Shingles Prevention Study
|
Phase 3 | |
Completed |
NCT04594226 -
Electroacupuncture Therapy for Treating Postherpetic Neuralgia
|
N/A | |
Completed |
NCT05140863 -
To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia
|
Phase 3 |